FDA panel recommends limiting Pfizer booster shots to Americans 65 and older, and those at high risk of severe COVID-19
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)